Explorer les evidences

76,3 %Among healthcare professionals in Sierra Leone surveyed from January to March 2022, 76.3% reported worries about unforeseen future effects of COVID-19 vaccines.

Sierra LeoneCOVID-19observé January to March 2022publié 2022Vaccineseurope_pmcdocument de 12 observations

68,8 %Antibiotics were used in 68.8% of the articles on COVID-19 patients with sepsis or septic shock.

Sierra LeoneCOVID-19 · sepsis · septic shockpublié 2020Sepsis and septic shock in COVID-19: a scoping review of the research dataeurope_pmcdocument de 17 observationsDOI 10.21203/rs.3.rs-30474/v1

11,4 %The prevalence of chronic kidney disease (CKD) among adults in Freetown, Sierra Leone was 11.4%.

Sierra Leonemaladie rénale chroniqueobservé 2019–2021publié 2023BMJ openeurope_pmcdocument de 6 observations

12 %Minority HIV-1 variants constituted 12% of sequenced samples in Sierra Leone.

Sierra LeoneVIH/sidapublié 2021Geneseurope_pmcdocument de 21 observationsDOI 10.3390/genes12091314

87,9 %The predominant HIV-1 subtype in Sierra Leone was CRF02_AG, accounting for 87.9% (95/108) of sequenced samples.

Sierra LeoneVIH/sidapublié 2021Geneseurope_pmcdocument de 21 observationsDOI 10.3390/genes12091314

16 %The likelihood of a positive HIV test was 16% higher in 2021 than in 2019 (prevalence ratio 1.16).

Sierra LeoneVIH/sidaobservé 2021publié 2024AIDS and behavioreurope_pmcdocument de 7 observations

58 300 vaccine_doses58,300 MVA-BN vaccine doses were delivered to Sierra Leone for Mpox.

Sierra LeonempoxAfrica CDCdocument de 72 observations

15,3 %Among 275 newly diagnosed people living with HIV (PWH) enrolled in the Sierra Leone HIV Cohort Study in Freetown from March to September 2021, 15.3% had HIV/HBV coinfection.

Sierra LeoneHIV/HBV coinfectionobservé March to September 2021publié 2022Journal of clinical medicineeurope_pmcdocument de 9 observations

74,7 %The proportion of drug-resistant TB cases that completed treatment decreased from 74.7% in the pre-COVID-19 period to 63.3% during the COVID-19 period.

Sierra Leonedrug-resistant TBobservé pre-COVID-19publié 2025Effect of the COVID-19 pandemic on drug-resistant tuberculosis treatment outcomes at a nateurope_pmcdocument de 9 observations

24,3 %HIV test was positive in 925 out of 3808 clients tested, representing 24.3%, at Connaught Hospital in Sierra Leone from January to December 2017.

Sierra LeoneVIH/sidaobservé January to December 2017publié 2019Low Partner Testing in High HIV Prevalence Setting in Freetown, Sierra Leone: A Retrospecteurope_pmcdocument de 5 observationsDOI 10.21203/rs.2.11135/v3

10 %Of the gram-negative bacteria, 10% were carbapenem-resistant Enterobacteriaceae.

Sierra Leonecarbapenem-resistant Enterobacteriaceaepublié 2022Therapeutic advances in infectious diseaseeurope_pmcdocument de 6 observations

60,1 %Among healthcare professionals in Sierra Leone surveyed from January to March 2022, 60.1% were classified as vaccine hesitant (above the 50th percentile of the VAX score).

Sierra LeoneCOVID-19observé January to March 2022publié 2022Vaccineseurope_pmcdocument de 12 observations

6,8 %The estimated prevalence of sepsis among COVID-19 patients ranges from 6.8% to 100%.

Sierra LeoneCOVID-19 · sepsispublié 2020Sepsis and septic shock in COVID-19: a scoping review of the research dataeurope_pmcdocument de 17 observationsDOI 10.21203/rs.3.rs-30474/v1

273 per_100000Sierra Leone has a TB incidence rate of 273 per 100,000 population in 2023.

Sierra Leonetuberculoseobservé 2023publié 2026PLOS global public healtheurope_pmcdocument de 6 observations

74 %The case fatality rate among patients with Ebola virus disease in Sierra Leone was 74%.

Sierra Leonemaladie à virus Ebolaobservé 2014publié 2014The New England journal of medicineeurope_pmcdocument de 14 observations

63,3 %The proportion of drug-resistant TB cases that completed treatment was 63.3% during the COVID-19 period.

Sierra Leonedrug-resistant TBobservé during COVID-19publié 2025Effect of the COVID-19 pandemic on drug-resistant tuberculosis treatment outcomes at a nateurope_pmcdocument de 9 observations

98,8 %Preoperative antibiotic use for caesarean section patients was 98.8% in 2023.

Sierra Leonesurgical site infectionsobservé 2023publié 2023Tropical medicine and infectious diseaseeurope_pmcdocument de 5 observationsDOI 10.3390/tropicalmed8080385

478 casesIn Sierra Leone, invasive aspergillosis is estimated at 478 annual cases.

Sierra Leoneinvasive aspergillosispublié 2021Therapeutic advances in infectious diseaseeurope_pmcdocument de 9 observations

8,7 %Among 275 newly diagnosed people living with HIV (PWH) enrolled in the Sierra Leone HIV Cohort Study in Freetown from March to September 2021, 8.7% had HIV/TB coinfection.

Sierra LeoneHIV/TB coinfectionobservé March to September 2021publié 2022Journal of clinical medicineeurope_pmcdocument de 9 observations

38 yearsThe median age of enrolled people with HIV in Freetown, Sierra Leone was 38 years.

Sierra LeoneVIH/sidaobservé April to June 2022publié 2023Vaccineseurope_pmcdocument de 5 observationsDOI 10.3390/vaccines11111685

Benin, Liberia, and Sierra Leone launched mass malaria vaccination in children on 25 April 2024.

Bénin · Liberia · Sierra Leonepaludismeobservé 25 April 2024HAL · Unilimdocument de 84 observations

21,1 %The prevalence of dyslipidaemia among adults in Freetown, Sierra Leone was 21.1%.

Sierra Leonedyslipidemiaobservé 2019–2021publié 2023BMJ openeurope_pmcdocument de 6 observations

8,3 %The prevalence of diabetes mellitus among adults in Freetown, Sierra Leone was 8.3%.

Sierra Leonediabète (non précisé)observé 2019–2021publié 2023BMJ openeurope_pmcdocument de 6 observations

24,1 %Among 761 HIV-exposed infants (HEIs), 176 (24.1%) received a second virological test 12 weeks after cessation of breastfeeding.

Sierra LeoneVIH/sidapublié 2026PLOS global public healtheurope_pmcdocument de 6 observations

21,1 %The prevalence of dyslipidemia among adults in Freetown, Sierra Leone was 21.1%.

Sierra Leonedyslipidemiaobservé 2019–2021publié 2023Burden of cardiometabolic risk factors and preclinical target organ damage among adults ineurope_pmcdocument de 8 observationsDOI 10.1101/2023.02.20.23286145